AC016745.3 Regulates the Transcription of AR Target Genes by Antagonizing NONO

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Androgen receptor (AR) signaling is crucial in prostate cancer (PCa) development.
• Long non-coding RNAs (lncRNAs) regulate tumorigenesis, but their roles in PCa are not fully understood.
• The specific functions of lncRNA AC016745.3 in PCa progression require elucidation.

Purpose of the Study:

• To investigate the function and molecular mechanisms of lncRNA AC016745.3 in prostate cancer.
• To determine the regulatory relationship between AC016745.3, androgen receptor (AR), and dihydrotestosterone (DHT).
• To explore the interaction between AC016745.3, AR, and the co-activator protein NONO.

Main Methods:

• Cell culture using LNCaP human prostate adenocarcinoma cells.
• Dihydrotestosterone (DHT) treatment to modulate AR signaling.
• Overexpression of lncRNA AC016745.3.
• RNA immunoprecipitation (RIP)-PCR to detect RNA-protein interactions.
• Cell proliferation and migration assays.
• AR target gene expression analysis.

Main Results:

• DHT suppresses AC016745.3 expression in an AR-dependent manner.
• Overexpression of AC016745.3 inhibits PCa cell proliferation and migration and reduces AR target gene expression.
• The protein NONO acts as an AR co-activator, enhancing AR transcriptional activity.
• AC016745.3 binds to both NONO and AR.
• NONO promotes PCa cell proliferation and migration, while AC016745.3 partially antagonizes these effects.
• AC016745.3 binding to NONO suppresses NONO's co-activation of AR.

Conclusions:

• AC016745.3 functions as a tumor suppressor in PCa by binding NONO and inhibiting AR-dependent transcription.
• DHT-induced suppression of AC016745.3 expression enhances NONO's oncogenic role in AR signaling.
• This study reveals a novel regulatory axis involving AC016745.3, NONO, and AR in prostate cancer development.